ArticlePloS one2008
Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- HPV-Driven Cervical Carcinogenesis: Genetic and Epigenetic Mechanisms and Diagnostic Approaches.International journal of molecular sciences · 2026Review
- Distribution of HPV genotypes and comparison of cervico-vaginal cytologies in PCR-detected HPV-positive patients: a retrospective observational study.Frontiers in global women's health · 2026Article
- Molecular Testing as Triage in Cervical Cancer Screening: Economic Evaluation Using Headroom Analysis.Cancers · 2025Article
- HPV vaccination willingness and behavior among patients with cervical intraepithelial neoplasia in low-resource areas of Western China: a cross-sectional study.Frontiers in public health · 2025Article
- Vaginal Microbiota and HPV in Latin America: A Narrative Review.Microorganisms · 2024Review
- The cervical microbiota of Hispanics living in Puerto Rico is nonoptimal regardless of HPV status.mSystems · 2023Article
- Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches.BMC infectious diseases · 2020Observational
- The Prevalence of HPV Genotypes in Iranian Population: An Update.Iranian journal of pathology · 2019Article
- Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.Human vaccines & immunotherapeutics · 2018Article
- Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.PloS one · 2018Article
- Differences in age-specific HPV prevalence between self-collected and health personnel collected specimen in a cross-sectional study in Ghana.Infectious agents and cancer · 2017Article
- Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.PloS one · 2016Article
- HPV infection and cervical neoplasia: associated risk factors.Infectious agents and cancer · 2015Article
- The role of acquired immunity in the spread of human papillomavirus (HPV): explorations with a microsimulation model.PloS one · 2015Article
- Prevalence and risk factors of human papillomavirus infection types 16/18/45 in a cohort of French females aged 15-23 years.Journal of epidemiology and global health · 2014Article
- Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany.BMC infectious diseases · 2013Article
- Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.BMC infectious diseases · 2013Article
- A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years.BMC infectious diseases · 2013Article
- Simultaneous detection and differentiation of human papillomavirus genotypes 6, 11, 16 and 18 by AllGlo quadruplex quantitative PCR.PloS one · 2012Article
- Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer.Virology journal · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfection with Human Papillomavirus (HPV) is a necessary event in the multi-step process of cervical carcinogenesis. Little is known about the natural history of HPV infection among unscreened young adults. As prophylactic vaccines are being developed to prevent specifically HPV 16 and 18 infections, shifts in prevalence in the post vaccine era may be expected. This study provides a unique opportunity to gather baseline data before changes by nationwide vaccination occur. METHODS AND PRINCIPAL
findingsThis cross-sectional study is part of a large prospective epidemiologic study performed among 2065 unscreened women aged 18 to 29 years. Women returned a self-collected cervico-vaginal specimen and filled out a questionnaire. All HPV DNA-positive samples (by SPF(10) DEIA) were genotyped using the INNO-LiPA HPV genotyping assay. HPV point prevalence in this sample was 19%. Low and high risk HPV prevalence was 9.1% and 11.8%, respectively. A single HPV-type was detected in 14.9% of all women, while multiple types were found in 4.1%. HPV-types 16 (2.8%) and 18 (1.4%) were found concomitantly in only 3 women (0.1%). There was an increase in HPV prevalence till 22 years. Multivariate analysis showed that number of lifetime sexual partners was the most powerful predictor of HPV positivity, followed by type of relationship, frequency of sexual contact, age, and number of sexual partners over the past 6 months. CONCLUSIONS AND SIGNIFICANCE: This study shows that factors independently associated with HPV prevalence are mainly related to sexual behaviour. Combination of these results with the relative low prevalence of HPV 16 and/or 18 may be promising for expanding the future target group for catch up vaccination. Furthermore, these results provide a basis for research on possible future shifts in HPV genotype prevalence, and enable a better estimate of the effect of HPV 16-18 vaccination on cervical cancer incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.